New hope for tough pancreatic cancer: targeted drug trial launches
NCT ID NCT07565155
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called lorigerlimab in people with advanced pancreatic cancer that has a specific genetic makeup (BRCA, PALB2, or RAD51C/D mutations). The goal is to see if the drug can shrink tumors. About 40 adults will take part, and the study is not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOLOGOUS RECOMBINATION DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Miami
Miami, Florida, 33136, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Four-Drug cocktail aims to shrink pancreatic tumors before surgery
- Exercise before and after pancreatic cancer surgery may speed recovery and chemotherapy start
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Could a simple blood test catch pancreatic cancer before It's too late?
- Light-Activated therapy targets pancreatic tumors during surgery